Table 3.
Projected US population estimates of early life BLLs in 2030*
| Panel A | |||
|---|---|---|---|
| BLL categories (µg/dL) | Population estimates | Percentage of population† | Margin of error (80% confidence) |
| <5 | 199,785,924 | 57.1 | 2,897,704 |
| 5–9.9 | 69,675,603 | 19.9 | 5,178,146 |
| 10–14.9 | 38,501,834 | 11.0 | 2,277,420 |
| 15–19.9 | 22,298,625 | 6.4 | 914,701 |
| 20–24.9 | 11,931,509 | 3.4 | 1,236,306 |
| 25–29.9 | 3,880,403 | 1.1 | 635,120 |
| ≥30 | 3,567,978 | 1.0 | 482,979 |
| Panel B | |||
| ≥5 | 149,855,952 | 42.9 | 5,916,217 |
| ≥10 | 80,180,349 | 22.9 | 2,861,541 |
| ≥15 | 41,678,515 | 11.9 | 1,732,564 |
| ≥20 | 19,379,890 | 5.5 | 1,471,428 |
| ≥25 | 7,448,381 | 2.1 | 797,901 |
*The total projected population in 2030 = 349,641,876.
†The sum of these population estimates is not equal to the population size due to rounding error.
Projections of early life BLLs in 2030. Over 43% of the US population will have had BLLs higher than 5 µg/dL in early childhood and nearly a quarter will have had BLLs of 10 µg/dL or greater. Early childhood lead exposure will remain a hallmark of the US population for the foreseeable future.